CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new antiviral drugs targeting the influenza virus by inhibiting its RNA polymerase complex. It focuses on creating small molecule inhibitors based on a peptide that blocks viral replication, utilizing advanced screening methods to identify effective candidates for further development.
The clock is counting down to the next influenza pandemic.
Since 1997, the avian influenza virus strain H5N1 has infected over 250 people worldwide with a fatality rate of ~60%, although so far without sustained human-to-human transmission.
In view of the very few efficacious drugs against influenza virus infections and the time it takes to develop a matching vaccine, there is an unmet worldwide need for new anti-influenza drugs.
The viral trimeric RNA polymerase complex, consisting of the subun…
PIKE PHARMA GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Freiburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Lithuania, VILNIUS
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH
Austria, Maria Enzersdorf
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
